Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 18395280.
- Also identified by DOI 10.1016/j.radonc.2008.03.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Outcome after radiochemotherapy (RCHT) with temozolomide (TMZ) versus radiotherapy (RT) for WHO grade III astrocytic tumors was evaluated. No significant difference in overall survival or progression-free survival between both groups was calculated. RCHT seems not to result in an improved outcome. Further randomized studies are needed to support these results.
Medical subject headings
- Antineoplastic Agents, Alkylating
- Astrocytoma
- Brain Neoplasms
- Dacarbazine